English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

• Target attainment was ≥85% for all drugs and regimens for non-VISA S. aureus using clinically derived targets. High Dose DAL and higher dosages of VAN were required to achieve >90% TA. For CoNS, TA was ≥90% for DAL and ORI and for only the highest dosage of VAN. As expected, VISA isolates showed poor TA% for all drugs. • Based on the specific data used in this analysis, current susceptibility breakpoints may need to be reevaluated. • Due to the higher protein binding of DAL, variability expected in patients would more profoundly affect target attainment. • Further studies are needed to clarify the ideal pharmacodynamic endpoints for these drugs. Relationship Between Target Attainment (%) and MIC Table 2. Clinical Endpoint Target Attainment (%)

Comparison of Dalbavancin, Oritavancin and Vancomycin Pharmacodynamics Using Clinical Targets Against ABSSSI Pathogens